Nasdaq halted traded in Puma Biotechnology (PBYI -4%) at 3:37 pm ET pending news.
Friday, July 21 is the FDA's action date for neratinib for HER2+ breast cancer.
Update: The FDA approves neratinib for the extended adjunctive treatment of early-stage HER2-overexpressed/amplified breast cancer, to follow adjuvant treatment with Roche's Herceptin (trastuzumab). Shares have yet to resume trading after hours.
Now read: Puma Stalks Up »